The Internet-Based MGS2 Control Sample: Self Report of Mental Illness
Supplemental Material
ajp_167_07_854_01.pdf (169 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×ajp_167_07_854_01.pdf (169 KB)
The authors thank the individuals who volunteered for the control sample for their participation. Data and biomaterials from the National Institute of Mental Health Genetics Initiative MGS2 (Molecular Genetics of Schizophrenia) control sample were collected by NorthShore University HealthSystem, Evanston, Ill., R01 MH-59571, Pablo V. Gejman, M.D. (collaboration coordinator; principal investigator), as part of a collaborative R01 application comprised of 10 sites. From 2003–2006, the principal investigators and co-investigators were: NorthShore University HealthSystem, Evanston, Ill., R01 MH-59571, Pablo V. Gejman, M.D. (collaboration coordinator; principal investigator), Alan R. Sanders, M.D.; Emory University School of Medicine, Atlanta, R01 MH-59587, Farooq Amin, M.D. (principal investigator); University of California, San Francisco, R01 MH-60870, William F. Byerley, M.D. (principal investigator); University of Iowa, Iowa City, IA, R01 MH-59566, Donald W. Black, M.D. (principal investigator), Raymond R. Crowe, M.D.; Washington University, St. Louis, Mo., R01 MH-60879, C. Robert Cloninger, M.D. (principal investigator); University of Colorado, Denver, R01 MH-59565, Robert Freedman, M.D. (principal investigator), Ann Olincy, M.D.; Stanford University, Palo Alto, Calif., R01 MH-61675, Douglas F. Levinson, M.D. (principal investigator); Louisiana State University, New Orleans, R01 MH-67257, Nancy G. Buccola, A.P.R.N., B.C., M.S.N. (principal investigator); University of Queensland, Brisbane, Queensland, Australia, R01 MH-59588, Bryan J. Mowry, M.D. (principal investigator); Mt. Sinai School of Medicine, New York, R01 MH-59586, Jeremy M. Silverman, Ph.D. (principal investigator). Our schizophrenia GWAS (genotyping and analyses) was supported by the Genetic Association Information Network (GAIN) and grants U01MH-79469 (Pablo V. Gejman, M.D.), U01MH-79470 (Douglas F. Levinson, M.D.), and R01MH-81800 (Pablo V. Gejman, M.D.). We also thank the individuals at each participating institution for their various contributions, especially Roberta Fishman, John Corcoran, and Douglas A. Fugman.